12th Expert Forum on Farm Animal Well-Being 12th Expert Forum on Farm Animal Well-Being The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
New Therapeutic Antibody Discovery Collaboration New Therapeutic Antibody Discovery Collaboration Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
Rethinking mental health care Rethinking mental health care Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Bringing focus to biliary tract and pancreatic cancers Bringing focus to biliary tract and pancreatic cancers The Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced biliary tract and pancreatic cancers.
GioTag Final Data GioTag Final Data Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
BTD for GlyT1 in Schizophrenia BTD for GlyT1 in Schizophrenia Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
The Boehringer Ingelheim Veterinary Scholars Program The Boehringer Ingelheim Veterinary Scholars Program The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
International Postdocs realize their potential in Biberach International Postdocs realize their potential in Biberach Three talented postdocs report on what they are working at Boehringer Ingelheim's research site in Biberach and what attracts them to the company.
Targeting HER2 in cancer: The story of zongertinib Targeting HER2 in cancer: The story of zongertinib We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
biolabs-heidelberg biolabs-heidelberg Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
1990-2023: Value through Innovation 1990-2023: Value through Innovation The Boehringer Ingelheim history from 1990 to 2023, with milestones
Uncommon_Mutations_Database Uncommon_Mutations_Database New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Ethical Business Practices Ethical Business Practices Suppliers shall conduct their business in an ethical manner and act with integrity.
Agreement-to-acquire-NBE-Therapeutics Agreement-to-acquire-NBE-Therapeutics Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Positive results Diabetic Macular Ischemia treatment Positive results Diabetic Macular Ischemia treatment HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
International Women's Day International Women's Day We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”